Literature DB >> 11559550

Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).

R Mentor-Marcel1, C A Lamartiniere, I E Eltoum, N M Greenberg, A Elgavish.   

Abstract

Latent prostate tumors are commonly found with similar frequency in many countries and ethnic groups. In contrast, aggressive prostate cancer (PC) is significantly less prevalent among Asian men, where the intake of soy products is very high. High consumption of foods containing soy results in high plasma, urine, and prostatic fluid concentrations of phytoestrogens, including genistein. The objective of the present study was to test the hypothesis that dietary genistein might prevent PC progression in a transgenic mouse model of PC (TRAMP). By 28-30 weeks of age, all TRAMP mice in the study had developed prostate tumors, with about half of them displaying well-differentiated prostatic adenocarcinoma (WD, score 4), and the other half divided between moderately differentiated (MD, score 5) and poorly differentiated adenocarcinoma (PD, score 6). Two lines of evidence supported the possibility that prostates with PD may represent a more advanced stage of PC in TRAMP mice: (a) the weight of prostates with PD was two orders of magnitude higher than that of prostates with WD or MD; and (b) expression of androgen receptor transcripts was altered in PD as compared with WD and MD. To test the potential of genistein to prevent the incidence of mice with PD, starting at 5-6 weeks of age, transgenic males were fed a phytoestrogen-free diet (AIN-76A) containing 0, 100, 250, or 500 mg of genistein per kg AIN-76A (25, 10, 17, and 7 mice/group, respectively). Mice were on the diet until they were 28-30 weeks of age. Each mouse was weighed once a week throughout the study. At necropsy, selected organs were weighed and prepared for histopathological evaluation. Serum levels of genistein in mice on diet containing 0, 250, or 500 mg of genistein per kg AIN-76A were 52.4 +/- 32.7, 138.9 +/- 69.6, and 397.3 +/- 104.9 nM, respectively, comparable with those found in Asian men on regular soy diet (276 nM). Using body and organ weights as indicators, dietary genistein had no toxic effect on TRAMP mice. The percentage of transgenic males that developed PD was reduced in a dose-dependent manner by dietary genistein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559550

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer.

Authors:  Jennifer H Ahn-Jarvis; Steven K Clinton; Elizabeth M Grainger; Kenneth M Riedl; Steven J Schwartz; Mei-Ling T Lee; Raul Cruz-Cano; Gregory S Young; Gregory B Lesinski; Yael Vodovotz
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

2.  Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.

Authors:  Gregory B Lesinski; Patrick K Reville; Thomas A Mace; Gregory S Young; Jennifer Ahn-Jarvis; Jennifer Thomas-Ahner; Yael Vodovotz; Zeenath Ameen; Elizabeth Grainger; Kenneth Riedl; Steven Schwartz; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

3.  Genistein and daidzein repress adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells via Wnt/β-catenin signalling or lipolysis.

Authors:  M-H Kim; J-S Park; M-S Seo; J-W Jung; Y-S Lee; K-S Kang
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

4.  Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention.

Authors:  Eric A Klein
Journal:  Rev Urol       Date:  2002

5.  Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.

Authors:  Rui Zhao; Nong Xiang; Fredrick E Domann; Weixiong Zhong
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

6.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

7.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

8.  Design and selection of soy breads used for evaluating isoflavone bioavailability in clinical trials.

Authors:  Jennifer H Ahn-Jarvis; Kenneth M Riedl; Steven J Schwartz; Yael Vodovotz
Journal:  J Agric Food Chem       Date:  2013-03-15       Impact factor: 5.279

9.  Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein.

Authors:  Yiwei Li; Mingxin Che; Sunita Bhagat; Kerrie-Lynn Ellis; Omer Kucuk; Daniel R Doerge; Judith Abrams; Michael L Cher; Fazlul H Sarkar
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 10.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.